GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (OSTO:ONCO) » Definitions » Deferred Policy Acquisition Costs

Oncopeptides AB (OSTO:ONCO) Deferred Policy Acquisition Costs


View and export this data going back to 2017. Start your Free Trial

What is Oncopeptides AB Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Oncopeptides AB Business Description

Industry
Traded in Other Exchanges
Address
Luntmakargatan 46, Stockholm, SWE, SE-111 37
Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and, in particular, multiple myeloma.